![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novavax Expects Late-Stage U.S./Mexico COVID-19 Vaccine Trial to Start Within Weeks
Novavax Expects Late-Stage U.S./Mexico COVID-19 Vaccine Trial to Start Within Weeks
![Novavax logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Novavax-logo.gif?t=1590614250&width=430)
December 1, 2020
Novavax said it will begin a delayed phase 3 trial in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, “in the coming weeks” and that its 15,000-person late-stage trial in the UK is now fully enrolled.
The company originally anticipated a mid-October start date for the North American trial but hit delays in securing enough vaccine doses. The new study aims to enroll up to 30,000 participants.
Maryland-based Novavax has teamed up with Japan’s Fujifilm to manufacture the doses at its plant in Morrisville, N.C.
Novavax hopes to have interim data from the UK phase 3 trial in early 2021 and plans to use that data as the basis for regulatory approval in the EU and the UK.
Upcoming Events
-
21Oct